Drug intelligence / Profile preview

AFM12

Development stage: Discontinued
Lead developer: Affimed
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AFM12 is an investigational, tetravalent bispecific antibody construct designed to engage natural killer (NK) cells for the treatment of B‑cell malignancies. Developed by Affimed, it simultaneously binds the NK-cell Fc receptor CD16A and the B-cell antigen CD19 to redirect and activate NK cells against CD19‑expressing tumor cells, promoting antibody-dependent cellular cytotoxicity. AFM12 is part of Affimed’s ROCK platform of NK cell engagers but its clinical development has been discontinued after preclinical and very early clinical efforts in non‑Hodgkin lymphoma.

Other names: CD16A/CD19-targeting innate cell engagerCD19/CD16A TandAbCD19 x CD16A bispecific antibodyCD-19 x CD16A bispecific antibodyCD 19 x CD16A bispecific antibodyCD19/CD16A ICE

Targets

CD19 (B lymphocyte antigen CD19)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on AFM12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFM12.

Explore the full profile